Targanta's Oritavancin Gets "Complete Response": Another Phase III Needed
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA threw Targanta a curveball in issuing a "complete response" letter Dec. 8, requiring an additional Phase III study for its complicated skin and skin structure infection treatment oritavancin before approval
You may also be interested in...
Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)
FDA Panel Votes For Theravance’s Telavancin, Against Targanta’s Oritavancin
Telavancin’s safety concerns did not stand in its way, but oritavancin’s efficacy concerns in treating MRSA did.
Big Pharma Still Hopeful For Next Mega Drugs To Supplement Sales
Drug makers need to continue investing in early-stage research to unveil the next $1 billion-plus drug, panelists at the Argyle conference agree.